EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study

Robyn-Jenia Wilcha iD, Peter J Goadsby iD

Cephalalgia · 2024

DOI: 10.1177/03331024241278911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Robyn-Jenia Wilcha und 1 weiteren Autor:innen. Beteiligte Einrichtung: NIHR King's Clinical Research Facility, SLaM Biomedical Research Centre, and Wolfson Sensory, Pain and Regeneration Centre, King's College London, Lo…. Hauptthemen laut MEDLINE: Tryptamines, Migraine Disorders, Tertiary Care Centers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triptans revolutionized the acute treatment of migraine; however, varied responses to triptans, as a result of poor efficacy and tolerability, are reported. A standardized definition of triptan non-response was recently proposed by the European Headache Federation (EHF). There is currently limited data available on the prevalence of triptan non-response.

Methods

We used clinic letters over a two-year duration to evaluate the triptan response and triptan efficacy or tolerability failure, or both, in a London-based tertiary headache service.

Results

In total, 419 adult migraine patients (females: 83.8%, age: 46 ± 18 years, chronic migraine: 88.5%) were included in a service evaluation. In line with the EHF definitions, “triptan non-response” was seen in 63.8% of patients (264/414), whereas 37.7% of patients (156/414) had failed at least two triptans (EHF “triptan resistant”) and 4.6% of patients (19/414) had failed at least three triptans, including a subcutaneous formulation (EHF “triptan refractory”). Notably, 21.3% of patients (88/414) had failed at least three triptans inclusive and exclusive of subcutaneous triptan use. Advancing age ( p < 0.001) and the presence of medication overuse ( p = 0.006) increased the probability of triptan response, whereas an increased number of failed preventives ( p < 0.001) and the use of calcitonin gene-related peptide monoclonal antibodies ( p = 0.022) increased the probability of triptan non-response. The largest proportion of patients responded to eletriptan (49.5%), followed by nasal zolmitriptan (44.4%) and rizatriptan (35.7%).

Conclusions

Our findings highlight an alarming prevalence of triptan non-response among adult migraineurs receiving treatment in a London-based tertiary headache service. It is imperative for clinicians to explore methods to optimize acute medication efficacy, whether this comprises changing to a triptan with a superior response rate, advocating for early intervention or considering alternative acute medication classes, such as gepants or ditans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TryptaminesMigraine DisordersTertiary Care CentersHumansMiddle AgedMaleFemaleLondonAdultRetrospective StudiesTreatment FailureAged

Stichwörter der Autor:innen

ditangepantmigrainetriptantriptan non-respondertriptan responder

Substanzen

Tryptamines

Autor:innen und Institutionen

  • NIHR King's Clinical Research Facility, SLaM Biomedical Research Centre, and Wolfson Sensory, Pain and Regeneration Centre, King's College London, London, UK.
  • Department of Neurology, University of California, Los Angeles, CA, USA.

ORCID-Profile: Robyn-Jenia Wilcha, Peter J Goadsby

Zitieren

APA

Wilcha, R. J., & Goadsby, P. J. (2024). Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study. Cephalalgia. https://doi.org/10.1177/03331024241278911

Vancouver

Wilcha RJ, Goadsby PJ. Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study. Cephalalgia. 2024. doi:10.1177/03331024241278911

BibTeX
@article{Wilcha2024,
  author = {Wilcha, Robyn-Jenia and Goadsby, Peter J},
  title = {Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241278911}
}
Kostenlos starten →